Acta Scientific Ophthalmology (ISSN: 2582-3191)

Case Report Volume 5 Issue 8

A Case Report of Recurrent Episodes of Periorbital Cellulitis (RPOC) and Facial Inflammation on a Background Of 1E Nasal Extranodal NKT Cell Lymphoma in Remission

Anna Gkountelia* and Wessam Mina

Department of Ophthalmology, BHRUT Hospitals, Queen’s Hospital, London, United Kingdom

*Corresponding Author: Anna Gkountelia, Department of Ophthalmology, BHRUT Hospitals, Queen’s Hospital, London, United Kingdom.

Received: May 16, 2022; Published: July 08, 2022

Abstract

Recurrent periorbital cellulitis is a rare complication of sinus disease. To discuss the cause and management of recurrent periorbital cellulitis (RPOC) in a 53-year‐old male patient with a medical history of stage 1E nasal extra nodal NKT cell lymphoma in remission (hard palate mass and left nasal cavity involvement) treated in the past with chemoradiotherapy, consolidative therapy and multiple sinus surgeries. Although periorbital cellulitis is a commonly encountered and treatable condition, recurrent periorbital cellulitis is rare and may be challenging to manage [1-5]. In our experience, the causes of recurrence vary, but resolution in this case was achieved by identifying the underlying cause through continuous clinical reassessment and by appropriate medical or surgical management.

Keywords: Periorbital Cellulitis; Surgery; Recurrent Periorbital Cellulitis (RPOC)

References

  1. Atfeh MS and Khalil HS. “Orbital infections: five-year case series, literature review and guideline development”. Journal of Laryngology and Otology 7 (2015): 670-676.
  2. Baring DE and Hilmi OJ. “An evidence based review of periorbital cellulitis”. Clinical Otolaryngology1 (2011): 57-64.
  3. Buchanan MA., et al. “Management of periorbital and orbital cellulitis”. Paediatrics and Child Health2 (2012): 72-77.
  4. Hauser A and Fogarasi S. “Periorbital and orbital cellulitis”. Pediatric Review6 (2010): 242-249.
  5. Rudloe TF., et al. “Acute periorbital infections: who needs emergent imaging?” Pediatrics 4 (2010): e719-726.
  6. Yang Y., et al. “Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study”. Blood 126 (2015): 1424-1432; quiz 1517.
  7. Kwong YL., et al. “Asian Oncology Summit. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009”. Lancet Oncology 10 (2009): 1093-1101.
  8. Hong H., et al. “A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group”. Leukemia 34 (2020): 2243-2248.
  9. Horwitz SM., et al. “NCCN guidelines insights: T-cell lymphomas, version 2.2018”. Journal of the National Comprehensive Cancer Network 16 (2018): 123-135.
  10. Yamaguchi M., et al. “Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type”. Blood 131 (2018): 2528-2540.
  11. Yamaguchi M., et al. “Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211”. Journal of Clinical Oncology 27 (2009): 5594-5600.
  12. Yamaguchi M., et al. “Treatments and outcomes of patients with extranodal natural killer/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan”. Journal of Clinical Oncology 35 (2017): 32-39.
  13. Kim SJ., et al. “Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: consortium for improving survival of lymphoma study”. Journal of Clinical Oncology 27 (2009): 6027-6032.
  14. Qi S., et al. “Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population”. Leukemia and Lymphoma 57 (2016): 2575-2583.

Citation

Citation: Anna Gkountelia and Wessam Mina. “A Case Report of Recurrent Episodes of Periorbital Cellulitis (RPOC) and Facial Inflammation on a Background Of 1E Nasal Extranodal NKT Cell Lymphoma in Remission".Acta Scientific Ophthalmology 5.8 (2022): 02-04.

Copyright

Copyright: © 2022 Anna Gkountelia and Wessam Mina. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days
ISI- IF1.042
JCR- IF0.24

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is November 30, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US